Private Advisor Group LLC Raises Position in Valeant Pharmaceuticals International, Inc. (VRX)

Private Advisor Group LLC increased its position in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 74.9% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 25,633 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,978 shares during the quarter. Private Advisor Group LLC’s holdings in Valeant Pharmaceuticals International were worth $428,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Gruss & Co. Inc. acquired a new position in Valeant Pharmaceuticals International during the first quarter worth $104,000. Harbor Advisors LLC acquired a new position in Valeant Pharmaceuticals International during the first quarter worth $110,000. WMS Partners LLC acquired a new position in Valeant Pharmaceuticals International during the first quarter worth $116,000. PNC Financial Services Group Inc. raised its holdings in Valeant Pharmaceuticals International by 33.7% during the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock worth $121,000 after purchasing an additional 2,763 shares during the last quarter. Finally, Baird Financial Group Inc. acquired a new position in Valeant Pharmaceuticals International during the first quarter worth $127,000. 50.49% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have recently weighed in on the company. Mizuho reissued an “underperform” rating and issued a $8.00 price target on shares of Valeant Pharmaceuticals International in a report on Tuesday, June 20th. Guggenheim assumed coverage on Valeant Pharmaceuticals International in a report on Saturday, June 17th. They issued a “buy” rating and a $18.00 price target for the company. Vetr raised Valeant Pharmaceuticals International from a “strong sell” rating to a “sell” rating and set a $12.46 price target for the company in a report on Monday. Piper Jaffray Companies reissued a “sell” rating and issued a $14.00 price target on shares of Valeant Pharmaceuticals International in a report on Sunday. Finally, Royal Bank Of Canada reissued a “market perform” rating and issued a $19.00 price target on shares of Valeant Pharmaceuticals International in a report on Tuesday, June 13th. Five research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $17.62.

WARNING: This news story was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/09/17/private-advisor-group-llc-raises-position-in-valeant-pharmaceuticals-international-inc-vrx.html.

Valeant Pharmaceuticals International, Inc. (VRX) opened at 13.92 on Friday. The stock’s market cap is $4.85 billion. The company has a 50-day moving average price of $14.39 and a 200-day moving average price of $13.19. Valeant Pharmaceuticals International, Inc. has a one year low of $8.31 and a one year high of $27.84.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.08. The company had revenue of $2.23 billion for the quarter, compared to the consensus estimate of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The firm’s revenue was down 7.7% compared to the same quarter last year. During the same period last year, the business posted ($0.88) earnings per share. On average, analysts anticipate that Valeant Pharmaceuticals International, Inc. will post $3.89 earnings per share for the current year.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De purchased 10,000 shares of the stock in a transaction dated Monday, August 21st. The shares were bought at an average cost of $14.33 per share, with a total value of $143,300.00. Following the completion of the transaction, the director now owns 77,479 shares in the company, valued at approximately $1,110,274.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 5.87% of the company’s stock.

Valeant Pharmaceuticals International Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply